World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 13 December 2021
Main ID:  NCT03405714
Date of registration: 12/01/2018
Prospective Registration: Yes
Primary sponsor: UCB Biopharma S.P.R.L.
Public title: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy
Scientific title: A Multicenter, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month < 16 Years of Age With Epilepsy
Date of first enrolment: June 1, 2018
Target sample size: 50
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT03405714
Study type:  Interventional
Study design:  Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 2
Countries of recruitment
Czechia Germany Hungary Italy Mexico Spain United States
Contacts
Name:     UCB Cares
Address: 
Telephone:
Email:
Affiliation:  001 844 599 2273 (UCB)
Key inclusion & exclusion criteria

Inclusion Criteria:

- Male or female from >= 1 month to < 16 years of age. For subjects who are < 1 year
from birth and who were preterm infants, the corrected gestational age should be used
for this entry requirement

- Weight >= 3 kg (6.6 lbs)

- Diagnosis of epilepsy

- Acceptable candidate for venipuncture and intravenous (iv) infusion

- Treatment with >=1 anti epileptic drug (AED; including BRV) without a change of dose
regimen for at least 7 days prior to Screening

- No treatment with vagus nerve stimulation (VNS), OR the subject is being treated with
VNS and the settings have been constant for >=7 days prior to Screening

- For female subjects: not of childbearing potential, OR of childbearing potential and
not sexually active/negative pregnancy test, OR of childbearing potential and sexually
active/negative pregnancy test/uses medically acceptable contraceptive methods

Exclusion Criteria:

- Subject has previously received iv Brivaracetam (BRV) in this study

- Subject is being treated with BRV at a dose >5mg/kg/day (rounded) or >200mg/day for
subjects with body weights >40kg

- Subject requires or is likely to require a change in concomitant antiepileptic drug(s)
(AED[s]), dose of concomitant AED(s), or formulation of AED(s) during the 7 days prior
to the intravenous (iv) pharmacokinetic (PK) Period

- Subject is likely, in the opinion of the Investigator, to require rescue medication
during the Initiating Oral BRV (IOB) Treatment or iv PK Periods

- Subject has experienced generalized convulsive status epilepticus in the 28 days prior
to Screening or during the Screening Period



Age minimum: 1 Month
Age maximum: 16 Years
Gender: All
Health Condition(s) or Problem(s) studied
Epilepsy
Intervention(s)
Drug: Brivaracetam
Primary Outcome(s)
Number of Participants With Adverse Events (AEs) [Time Frame: From Screening until last visit (up to Day 68)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 [Time Frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- Bolus [Time Frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- 15 Minutes [Time Frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 [Time Frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 by Infusion Duration- 15 Minutes [Time Frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- 15 Minutes [Time Frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration- Bolus [Time Frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- 15 Minutes [Time Frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 [Time Frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 by Infusion Duration- 15 Minutes [Time Frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)]
Number of Participant Withdrawals Due to Adverse Events [Time Frame: From Screening until last visit (up to Day 68)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- 15 Minutes [Time Frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 3 by Infusion Duration- Bolus [Time Frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 [Time Frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 [Time Frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 [Time Frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 [Time Frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 3 by Infusion Duration - 15 Minutes [Time Frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 3 (Day 1 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 4 by Infusion Duration- Bolus [Time Frame: At 3 hours post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 by Infusion Duration- Bolus [Time Frame: At <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 [Time Frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 3 by Infusion Duration- Bolus [Time Frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 3 (Day 1 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 3 Hours, Visit 5 by Infusion Duration- 15 Minutes [Time Frame: Blood samples were collected at 3 hours post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 5 by Infusion Duration- Bolus [Time Frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 5 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 [Time Frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 4 by Infusion Duration- Bolus [Time Frame: At 15 minutes post-initiation of iv BRV infusion at Visit 4 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Postdose 15 Minutes, Visit 5 by Infusion Duration- Bolus [Time Frame: Blood samples were collected at 15 minutes post-initiation of iv BRV infusion at Visit 5 (Day 2 of IV PK period)]
Plasma Concentration of Brivaracetam (BRV) at Predose (<=1 Hour), Visit 4 by Infusion Duration- 15 Minutes [Time Frame: Blood samples were collected at <= 1 hour pre-initiation of intravenous (iv) BRV infusion at Visit 4 (Day 2 of IV PK period)]
Secondary Outcome(s)
Secondary ID(s)
2016-002452-25
EP0065
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 26/11/2021
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT03405714
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history